Methylated B3GAT2 and ZNF793 Are Potential Detection Biomarkers for Barrett's Esophagus

  title={Methylated B3GAT2 and ZNF793 Are Potential Detection Biomarkers for Barrett's Esophagus},
  author={Ming Yu and Rachele M. O'Leary and Andrew M. Kaz and Shelli M. Morris and Kelly T Carter and Amitabh Chak and Apoorva Krishna Chandar and Joseph E. Willis and Helen R Moinova and Sanford D. Markowitz and Dean E. Brenner and Sharmila Anandabapasathy and Maria Westerhoff and Chao-Jen Wong and Nicholas J. Shaheen and Yanwen Chen and Jill S. Barnholtz-Sloan and William M. Grady},
  journal={Cancer Epidemiology, Biomarkers \& Prevention},
  pages={1890 - 1897}
Background: Barrett's esophagus (BE) is a preneoplastic condition in which normal esophageal squamous epithelium (SQ) is replaced by specialized intestinal metaplasia. It is the presumed precursor for esophageal adenocarcinoma (EAC) as well as the strongest risk factor for this cancer. Unfortunately, many patients with BE go undiagnosed under the current BE screening guidelines. The development of noninvasive and accurate BE detection assays could potentially identify many of these undiagnosed… 
Highly Discriminant Methylated DNA Markers for the Non‐endoscopic Detection of Barrett's Esophagus
BACKGROUND: Minimally invasive methods have been described to detect Barrett's esophagus (BE), but are limited by subjectivity and suboptimal accuracy. We identified methylated DNA markers (MDMs) for
Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus
  • W. Grady, M. Yu
  • Biology, Medicine
    Digestive Diseases and Sciences
  • 2018
B Barrett’s esophagus provides researchers with a unique model to characterize the process by which a carcinoma arises from its precursor lesion, and new insight is provided into the evolutionary forces underlying the molecular alterations seen in BE and EAC and into the molecular pathogenesis of EAC.
Follow-Up Study Confirms the Presence of Gastric Cancer DNA Methylation Hallmarks in High-Risk Precursor Lesions
It is ascertained that intestinal metaplasia partially recapitulates patterns of aberrant methylation of intestinal type of gastric cancer, independently of the H. pylori status, which supports the need to investigate the practical utilities of the quantification of DNA methylation in candidate genes as a marker for disease progression.
Genome-wide DNA methylation profiling identifies epigenetic signatures of gastric cardiac intestinal metaplasia
The results suggest the implication of alterations in DNA methylation in gastric cardiac IM and highlight that HOXA5 hypermethylation may be a promising epigenetic biomarker, emphasizing the role of aberrant HOX a5 expression in the pathogenesis of gastric medical metaplasia.
CEBP FOCUS Barrett’s Esophagus and Esophageal Adenocarcinoma Biomarkers A C
Esophageal adenocarcinoma is a major cause of cancer-related morbidity and mortality in Western countries. The incidences of esophageal adenocarcinoma and its precursor Barrett’s esophagus have
Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers
An updated overview of the molecular pathology of Barrett's esophagus and esophageal adenocarcinoma and emerging molecular biomarker assays, as well as the role of EDRN in biomarker discovery and validation, will be discussed.
Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer.
Epigenetic alterations have emerged as one of most robust classes of biomarkers and are the basis for a growing number of clinical tests for cancer screening and surveillance.
Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy.
The state-of-the-art technologies for early diagnosis and minimally invasive treatment of esophageal cancer using resection and ablation technologies supported by evidence from randomized controlled trials are reviewed.
Environmentally Induced Alterations in the Epigenome Affecting Obesity and Cancer in Minority Populations
Evidence for the influence of environmental exposures on obesity and how epigenetic alterations may contribute to cancers that disproportionately affect minority populations exhibit disparities in incidence and mortality are summarized in this chapter.


DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses
Methylation microarrays were utilized to compare the global gene methylation status of a collection of normal squamous, BE, BE + high-grade dysplasia (HGD) and EAC cases and found distinct global methylation signatures, as well as differential methylation of specific genes, that discriminated these histological groups.
Aberrant Vimentin Methylation Is Characteristic of Upper Gastrointestinal Pathologies
These findings establish aberrant vimentin methylation as a highly common epigenetic alteration in neoplasia of the upper gastrointestinal tract and show that Barrett's esophagus, even without dysplasia, already contains epigenetic alterations characteristic of adenocarcinoma.
Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis
In conclusion, mutations in EAC driver genes generally occur exceptionally early in disease development with profound implications for diagnostic and therapeutic strategies.
Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.
The risk of malignant progression among patients with BE is found to be lower than previously reported, suggesting that currently recommended surveillance strategies may not be cost-effective.
Surveillance and survival in Barrett's adenocarcinomas: a population-based study.
Even if current surveillance techniques are effective, they are unlikely to substantially impact the population's mortality from esophageal cancer; better methods are needed to identify at risk patients.
Risk factors for Barrett's esophagus: A case‐control study
Results from this study point out that long‐standing GERD symptoms, hiatal hernia and possibly alcohol consumption are risk factors in the development of the BE and E.
Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer.
Genome-wide alterations in DNA methylation occur during early stages of progression of tubular adenomas to cancer, revealing heterogeneity in the pathogenesis of colorectal cancer, even at the adenoma step of the process.
Unique DNA methylome profiles in CpG island methylator phenotype colon cancers.
Observations indicate that CIMP tumors have specific defects in controlling both DNA methylation seeding and spreading and serve as an important first step in delineating molecular mechanisms that control these processes.
Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis.
Patients with BE are at low risk of malignant progression and predominantly die due to causes other than EAC, which undermines the cost-effectiveness of BE surveillance and supports the search for valid risk stratification tools to identify the minority of patients that are likely to benefit from surveillance.
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
A systematic, stepwise screen of 195 CpG island methylation markers using MethyLight technology found that CIMP-positive (CIMP+) tumors convincingly represent a distinct subset, encompassing almost all cases of tumors with BRAFmutation (odds ratio = 203).